# LOTTE Biologics Completes Construction of Songdo Bio Campus Plant 1 and Obtains Approval for Use

- Link: https://www.thailand-business-news.com/pr-news/lotte-biologics-completes-construction-of-songdo-bio-campus-plant-1-and-obtains-approval-for-use
- Published: 2026-06-22T07:00:00+07:00
- Author: PR Newswire

|   |

INCHEON, South Korea and SAN DIEGO, June 22, 2026 /PRNewswire/ — LOTTE Biologics
announced that it has completed major construction and obtained approval for use
for Plant 1 at its Songdo Bio Campus in Incheon, South Korea.

 [⌊[Picture] LOTTE Biologics Songdo Bio Campus Factory 1⌉](https://mmx.prnasia.com/media/MS1869417/01ff6a367da249ce88201a65ef5cc679.jpg?id=OA2725916&p=medium600)
[
Picture] LOTTE Biologics Songdo Bio Campus Factory 1

The milestone was achieved approximately two years after the start of construction
in 2024, representing an exceptionally fast project execution timeline among global
biologics manufacturing facility construction projects.

The approval for use confirms that the physical construction of the facility has
been completed, including site development, building and civil engineering works,
production equipment, piping, electrical systems, and control systems. As biologics
manufacturing facilities must support complex cell culture processes while meeting
global cGMP standards, their construction requires advanced design and engineering
capabilities as well as systematic quality management.

LOTTE Biologics incorporated operational experience and manufacturing know-how from
its Syracuse Bio Campus into the construction of Songdo Plant 1. From the design
stage, the company implemented an automated Manufacturing Control System, or MCS,
to enhance production efficiency and quality competitiveness. The facility has also
been designed to maximize the company’s ability to provide customized support for
customers during future commercial manufacturing.

Songdo Plant 1 is a 120,000-liter antibody manufacturing facility, equipped with
eight 15,000-liter stainless-steel bioreactors to support large-scale commercial
production demand. The facility also incorporates advanced bioprocessing technologies,
including higher-titer cell culture and perfusion processes. In addition, LOTTE 
Biologics introduced an automated warehouse and real-time monitoring-based operating
systems to improve manufacturing stability and operational efficiency.

Through its dual-site strategy linking Songdo Bio Campus with Syracuse Bio Campus
in New York, the United States, LOTTE Biologics is now positioned to provide integrated
CDMO services that connect early-stage clinical production with large-scale commercial
manufacturing. Under this model, the Syracuse Bio Campus will support early-stage
customer projects and clinical supply, while Songdo Plant 1 will serve as a large-
scale commercial manufacturing base. This dual-site structure enables the company
to respond flexibly to a broad range of customer needs, from small-scale projects
to large commercial production volumes.

Based on its manufacturing network spanning the United States and Korea, LOTTE Biologics
anticipates enhanced support for customers’ regional supply strategies and growing
demand for supply chain risk diversification.

LOTTE Biologics plans to begin full-scale commissioning and production system validation
in the second half of this year. Through these efforts, the company aims to secure
GMP manufacturing readiness early and establish a stable foundation for commercial
manufacturing to meet global customer demand. The company also plans to continue
strengthening production efficiency and quality competitiveness through data-driven
process operations and advanced digital systems.

"Completing major construction and obtaining use approval for Songdo Plant 1 approximately
two years after groundbreaking is the result of our employees’ capabilities, dedicated
project execution, and strategic support and collaboration across the LOTTE Group,"
said James Park, CEO of LOTTE Biologics. "Based on our global manufacturing platform
connecting Syracuse and Songdo, we will establish ourselves as a trusted CDMO partner
for customers worldwide."

He added, "With an integrated manufacturing system that combines speed, quality,
and production flexibility, we will proactively respond to the diverse development
and commercialization needs of global customers and continue growing into a world-
class CDMO company."

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [LOTTE Biologics Completes Construction of Songdo Bio Campus Plant 1 and Obtains Approval for Use ](http://www.prnasia.com/story/archive/4987854_CN87854_0?rand=184833)